Regeneron Pharmaceuticals Inc. (REGN) Financial Statements (2025 and earlier)

Company Profile

Business Address 777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
State of Incorp. NY
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,01310,8457,7425,6953,5873,214
Cash and cash equivalent2,4882,7303,1062,8862,1941,618
Short-term investments6,5248,1154,6362,8091,3931,597
Restricted cash and investments1     
Receivables6,2125,6675,3296,0373,1122,361
Inventory, net of allowances, customer advances and progress billings3,0872,5812,4021,9511,9171,416
Inventory3,0872,5812,4021,9511,9171,416
Other undisclosed current assets3483874113321,164699
Total current assets:18,66119,47915,88414,0159,7797,689
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 591606620631646 
Operating lease, right-of-use asset 21778    
Property, plant and equipment      2,890
Long-term investments and receivables8,9005,3976,5926,8383,1363,257
Long-term investments8,9005,3976,5926,8383,1363,257
Intangible assets, net (including goodwill)1,1491,039916   
Intangible assets, net (excluding goodwill)1,1491,039916   
Restricted cash and investments  8    
Deferred income tax assets3,3142,5751,724877859824
Other noncurrent assets1,136444336223168145
Other undisclosed noncurrent assets3,7913,4553,1432,8512,576 
Total noncurrent assets:19,09913,60113,33011,4207,3847,116
TOTAL ASSETS:37,75933,08029,21525,43517,16314,805
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,5272,3582,0742,2071,5221,087
Taxes payable3262049
Employee-related liabilities441466344
Accounts payable790607589564476 
Accrued liabilities 1,4251,2851,135384330301
Other undisclosed accounts payable and accrued liabilities 312466350492231392
Deferred revenue628459478442 592
Debt    720  
Other liabilities     122 
Other undisclosed current liabilities7906075895641,053418
Total current liabilities:3,9443,4233,1413,9332,6972,097
Noncurrent Liabilities
Long-term debt and lease obligation2,7042,7032,7011,9802,696714
Long-term debt, excluding current maturities1,9841,9831,9811,9801,979 
Finance lease, liability720720720 717714
Liabilities, other than long-term debt1,757981708754 905
Deferred revenue1861277073 619
Other liabilities1,571854638680 286
Other undisclosed noncurrent liabilities     745 
Total noncurrent liabilities:4,4623,6843,4092,7343,4411,619
Total liabilities:8,4067,1076,5516,6666,1383,716
Equity
Equity, attributable to parent, including:29,35425,97322,66418,76911,02511,090
Treasury stock, value(15,167)(12,560)(10,353)(8,261)(6,613)(740)
Additional paid in capital12,85611,3549,9498,0886,7164,429
Accumulated other comprehensive income (loss)(8)(81)(239)(26)2921
Retained earnings31,67327,26023,30718,96810,8937,380
Other undisclosed equity, attributable to parent000000
Total equity:29,35425,97322,66418,76911,02511,090
TOTAL LIABILITIES AND EQUITY:37,75933,08029,21525,43517,16314,805

Income Statement (P&L) ($ in millions)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues14,20213,11712,17316,0728,4977,863
Cost of revenue(2,125)(2,000)(1,726)(2,392)(840)(768)
Cost of product and service sold (126)(102)(259)(457)(39)(74)
Gross profit:12,07711,11710,44713,6807,6587,096
Operating expenses(8,086)(7,070)(5,708)(4,733)(4,081)(4,886)
Other operating income (expense), net(53)29046280 
Other undisclosed operating income (loss)53(2)(90)(46)(280) 
Operating income:3,9914,0474,7398,9473,5772,210
Nonoperating income789152120379234219
Other nonoperating income844225179436291250
Interest and debt expense(55)(73)(59)(57)(57)(30)
Other undisclosed income from continuing operations before equity method investments, income taxes     5730
Income from continuing operations before equity method investments, income taxes:4,7254,1264,7999,2693,8102,429
Other undisclosed income from continuing operations before income taxes55735957  
Income from continuing operations before income taxes:4,7804,1994,8599,3263,8102,429
Income tax expense(367)(246)(520)(1,251)(297)(313)
Income from continuing operations:4,4133,9544,3388,0753,5132,116
Income before gain (loss) on sale of properties:8,0753,5132,116
Net income available to common stockholders, diluted:4,4133,9544,3388,0753,5132,116

Comprehensive Income ($ in millions)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income:4,4133,9544,3388,0753,5132,116
Other comprehensive income (loss) 158(213)(56)  
Comprehensive income:4,4134,1124,1268,0203,5132,116
Other undisclosed comprehensive income, net of tax, attributable to parent73   833
Comprehensive income, net of tax, attributable to parent:4,4864,1124,1268,0203,5212,149

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: